ProKidney (PROK) Competitors

Vaxcyte (NASDAQ:PCVX) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Does the media refer more to PCVX or PROK?

In the previous week, ProKidney had 17 more articles in the media than Vaxcyte. MarketBeat recorded 19 mentions for ProKidney and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.52 beat ProKidney's score of 0.82 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ProKidney	6 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation & earnings, PCVX or PROK?

ProKidney has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$463.93M	-$3.99	-9.37
ProKidney	$80K	12,878.80	-$61.19M	-$0.60	-5.87

Do analysts prefer PCVX or PROK?

Vaxcyte currently has a consensus price target of $136.50, suggesting a potential upside of 265.27%. ProKidney has a consensus price target of $6.25, suggesting a potential upside of 77.56%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Vaxcyte is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
ProKidney	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Do institutionals & insiders have more ownership in PCVX or PROK?

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is PCVX or PROK more profitable?

ProKidney's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-17.12%	-16.26%
ProKidney	N/A	N/A	-15.03%

Which has more volatility & risk, PCVX or PROK?

Vaxcyte has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Summary

ProKidney beats Vaxcyte on 9 of the 15 factors compared between the two stocks.